What question did this study set out to answer?

This study aims to compare treatment persistence and serum drug levels between subcutaneous and intravenous infliximab in patients with inflammatory bowel disease.

January 23, 2026Journal of Crohn s and Colitis

P1179Switching from intravenous to subcutaneous infliximab is equally effective and increases the serum drug levels

View Full Paper

Ask AI

Bookmark

This study aims to compare treatment persistence and serum drug levels between subcutaneous and intravenous infliximab in patients with inflammatory bowel disease.
Prospective cohort design comparing patients on subcutaneous infliximab to those on intravenous therapy.
Participants included those who switched from intravenous to subcutaneous infliximab and those who continued on intravenous therapy.
Serum infliximab trough levels were measured before and after switching.
Treatment continuation rates were analyzed for both routes of administration.
Treatment continuation rates were similar between subcutaneous (77.8% for primary-sc and 91.7% for switch) and intravenous regimens (87.5% for primary and 89.3% for switch).
92.3% of patients switching to subcutaneous infliximab showed an increase in serum infliximab levels after treatment.
The median serum infliximab level increased significantly from 11.1μg/ml before the switch to 20μg/ml after switching (P = 0.007).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Cohort study compares treatment persistence and serum drug levels in patients using subcutaneous and intravenous infliximab, suggesting effective maintenance therapy alternatives.

Cite This Study

Avatziadis et al. (2026) studied this question.

synapsesocial.com/papers/69730f18c8125b09b0d1ed77 https://doi.org/10.1093/ecco-jcc/jjaf231.1360

View Full Paper

Ask AI

Bookmark

Implication

Cohort study compares treatment persistence and serum drug levels in patients using subcutaneous and intravenous infliximab, suggesting effective maintenance therapy alternatives.

P1179Switching from intravenous to subcutaneous infliximab is equally effective and increases the serum drug levels

Key Points

Discussion

Implication

Cite This Study

P1179Switching from intravenous to subcutaneous infliximab is equally effective and increases the serum drug levels

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider